Advanced search
Publication Cover
Cancer Management and Research Volume 11, 2019 - Issue
Submit an article Journal homepage
107
Views
21
CrossRef citations to date
0
Altmetric
Original Research

The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer

Zhiyao Fan1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Kun Fan1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Yitao Gong1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Qiuyi Huang1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Chao Yang1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
He Cheng1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Kaizhou Jin1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Quanxing Ni1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Xianjun Yu1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-6697-7143
ORCID Icon,
Guopei Luo1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected] [email protected]
&
Chen Liu1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0001-8155-773X
ORCID Icon show all
Pages 8781-8788 | Published online: 30 Sep 2019

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.2144229313949
  • Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–1617. doi:10.1056/NEJMra090155720427809
  • Audrey V, Joseph H, Rich S, Hruban RH, Michael G. Pancreatic cancer. Lancet. 2011;378(9791):607–620. doi:10.1016/S0140-6736(10)62307-021620466
  • Sabater L, Muñoz E, Roselló S, et al. Borderline resectable pancreatic cancer. Challenges and controversies. Cancer Treat Rev. 2018;68:124–135. doi:10.1016/j.ctrv.2018.06.00629957372
  • Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15:333–348. doi:10.1038/s41575-018-0005-x29717230
  • Luo G, Guo M, Liu Z, et al. Blood neutrophil–lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol. 2015;22(2):670–676. doi:10.1245/s10434-014-4021-y25155401
  • Jin W, Xu HX, Zhang SR, et al. Tumor-infiltrating NETs predict postsurgical survival in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2018;26(2):635–643.30374923
  • Kruger S, Heinemann V, Ross C, et al. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann Oncol. 2018;29(12):2348–2355.30346475
  • Antonioli L, Blandizzi C, Pacher P, Haskó G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013;13(12):842–857. doi:10.1038/nrc361324226193
  • Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29(8):1093–1102. doi:10.1038/onc.2009.41619946335
  • McMillan DC, Morrison DS, Talwar D, Horgan PG, Proctor MJ. Inflammation-based prognostic scores to predict outcome in patients with cancer. J Clin Oncol. 2011;29(15_suppl):e21154. doi:10.1200/jco.2011.29.15_suppl.e21154
  • Laird BJ, Kaasa S, McMillan DC, et al. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 2013;19(19):5456–5464. doi:10.1158/1078-0432.CCR-13-106623938289
  • Lee S, Kwon HC, Kim SH, et al. Capecitabine monotherapy and the clinical significance of neutrophil-lymphocyte ratio versus platelet-lymphocyte ratio in patients with metastatic colorectal cancer. J Clin Oncol. 2012;30(4_suppl):660. doi:10.1200/jco.2012.30.4_suppl.660
  • Kim J, Kim HJ. Neutrophil lymphocyte ratio (NLR) change after systemic treatment as a predictive factor of cancer specific survival in stage IV breast cancer. J Clin Oncol. 2015;33(28_suppl):29. doi:10.1200/jco.2015.33.28_suppl.2925403204
  • Kinoshita A, Onoda H, Imai N, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22(3):803–810. doi:10.1245/s10434-014-4048-025190127
  • Wei XL, Wang FH, Zhang DS, et al. A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. BMC Cancer. 2015;15(1):350. doi:10.1186/s12885-015-1584-325934640
  • Lu J, Xu BB, Zheng ZF, et al. CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial. Gastric Cancer. 2018;22(3):536–545.30377862
  • Ni XF, Wu J, Ji M, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer. Asia Pac J Clin Oncol. 2018;14:402–409. doi:10.1111/ajco.2018.14.issue-630178541
  • Liu Z, Jin K, Guo M, et al. Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic cancer. Ann Surg Oncol. 2016;24(2):561–568.27650825
  • Guo S, He X, Chen Q, et al. The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients. BMC Cancer. 2017;17(1):171. doi:10.1186/s12885-017-3119-628264659
  • Liu Y, Chen S, Zheng C, et al. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC Cancer. 2017;17(1):285. doi:10.1186/s12885-017-3220-x28431566
  • Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-420180029
  • Budczies J, Klauschen F, Sinn BV, et al. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7(12):e51862. doi:10.1371/journal.pone.005186223251644
  • Catanzaro JM, Sheshadri N, Pan JA, et al. Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4. Nat Commun. 2014;5:3729. doi:10.1038/ncomms597224759783
  • Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine. 2008;43(3):374–379. doi:10.1016/j.cyto.2008.07.01418701317
  • Imaoka H, Mizuno N, Hara K, et al. Evaluation of modified glasgow prognostic score for pancreatic cancer: a retrospective cohort study. Pancreas. 2015;45(2):211–217.
  • Caraceni P, Tufoni M, Bonavita ME. Clinical use of albumin. Blood Transfusion. 2013;11(3):S18–S25. doi:10.2450/2013.005s24333308
  • Wang Y, Xiao X, Wang T, et al. A survival model in locally advanced and metastatic pancreatic ductal adenocarcinoma. J Cancer. 2018;9(7):1301–1307. doi:10.7150/jca.2398429675111
  • Haruki K, Shiba H, Shirai Y, et al. The C-reactive protein to albumin ratio predicts long-term outcomes in patients with pancreatic cancer after pancreatic resection. World J Surg. 2016;40:2254–2260. doi:10.1007/s00268-016-3491-426956901
  • Yoshikawa T, Aoyama T, Kuwabara H, et al. Body weight loss after surgery as an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. J Clin Oncol. 2012;30(4_suppl):125. doi:10.1200/jco.2012.30.4_suppl.125
  • Rogers PC. Nutritional status as a prognostic indicator for pediatric malignancies. J Clin Oncol. 2014;32(13):1293–1294. doi:10.1200/JCO.2014.55.061624687820

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.